Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials

Telmisartan reduced mean ambulatory systolic blood pressure by 5.8 mm Hg compared to ramipril over the last 6 hours of a 24-hour dosing cycle.

• Patients with essential hypertension had a mean baseline ambulatory blood pressure of approximately 148/93 mm Hg.
• After 8 weeks, telmisartan showed a significant reduction in mean ambulatory systolic and diastolic blood pressure compared to ramipril.
• At 14 weeks, the adjusted mean treatment differences remained significantly in favor of telmisartan for both systolic and diastolic blood pressure.
• Secondary endpoints, including 24-hour ambulatory blood pressure monitoring, also indicated significant advantages for telmisartan.
• Both telmisartan and ramipril were well tolerated, with fewer adverse events, such as cough, reported for telmisartan.

AI simplified